Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program | ||
By: GlobeNewswire - 12 May 2021 | Back to overview list |
|
Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600 SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its contract research organization (CRO), from two key studies for the Company’s Targeted Therapeutics program. The studies involved both the first functional clinical study of the Drug Delivery System (DDS), and the first preclinical study of PGN-600 (liquid tofacitinib delivered by DDS), one of the Company’s drug/DDS combination products. Progenity’s Targeted Therapeutics program consists of drug device combination products that allow the delivery of high concentrations of proprietary drug formulations by a novel, orally ingestible capsule to the precise site of disease along the GI tract. The DDS capsule is designed to maximize the available dose at the site of disease and reduce systemic toxicity. The Company’s two lead combination product candidates, PGN-001 (liquid adalimumab delivered by DDS) and PGN-600, are being developed with an initial priority for ulcerative colitis, part of the estimated $15 billion inflammatory bowel disease (IBD) market. The company has completed its first clinical study of the fully autonomous DDS device in twelve healthy adults. This study evaluated the capsule’s targeting, safety and tolerability within the gastrointestinal tract and collected the first clinical data on the ability of the DDS to auto-locate and accurately deliver a payload to the proximal colon, a key delivery site for the treatment of ulcerative colitis and Crohn’s disease. The single administration study used the well-established method of scintigraphic characterization to validate the DDS localization and the drug delivery mechanism by using a saline solution payload that included radioisotopes. Initial analysis of the study results suggests the DDS was well tolerated and the majority of DDS devices functioned as intended and could accurately identify entry into the colon, trigger release of a liquid payload, and achieve pan-colon distribution. “These results support the use of the DDS for the company’s lead ulcerative colitis combination product candidate, and potentially for uses of the DDS with other therapeutics to create combination products targeting other GI diseases. By delivering solubilized therapeutics directly to the site of disease in the GI tract, the DDS can potentially improve efficacy through increased localized drug concentration while minimizing harmful side effects associated with systemic drug delivery,” said William Sandborn MD, Professor of Medicine at the University of California San Diego. Progenity also completed a preclinical study evaluating the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of a seven-day administration of PGN-600 (liquid tofacitinib delivered by DDS) at doses of 10mg or 25mg per day, with direct comparison to a standard orally administered tofacitinib tablet at 10mg per day in 12 canines. This was the first study evaluating PGN-600 as a combination product of the company’s proprietary solubilized formulation of tofacitinib delivered with the DDS. Initial analysis of the study results suggests PGN-600 was well tolerated, the DDS functioned as intended in the majority of doses, and resulted in significantly higher tofacitinib concentrations in colon tissue, while also showing much lower systemic blood concentrations than the equivalent 10mg dose delivered by standard oral tablet. Tissue levels and tissue to plasma ratios of tofacitinib levels along the length of the colon were at least 25x and 50x higher respectively with PGN-600 at 10mg and 25mg daily compared to the standard oral tablet formulation of 10mg. These results demonstrate that the proprietary liquid formulation of PGN-600 can achieve pan-colonic distribution and facilitate mucosal penetration. In addition, no evidence of tissue damage was observed by histology at either 10mg or 25mg of PGN-600. The results of this study should help inform the clinical dosing of PGN-600, with data suggesting that a dose lower than currently commercially available tofacitinib formulations may lead to significantly greater tissue drug concentrations and materially reduced systemic exposure, potentially resulting in enhanced efficacy and lower systemic side effects. “The data from these two studies when considered together provide further evidence that local delivery of solubilized therapeutics using Progenity’s proprietary liquid formulations to the site of disease is enabled by the DDS and may lead to improved pharmacokinetic and pharmacodynamic effects as compared to systemic administration,” said Harry Stylli, PhD, CEO, chairman of the board and co-founder of Progenity. “This approach has the potential to enhance any compatible drug and holds promise for monoclonal biotherapeutics such as adalimumab. Given these results, we are proceeding with activities to enable clinical evaluation of both tofacitinib and adalimumab drug candidates (PGN-001 and PGN-600) with the ultimate goal of significantly improving treatment outcomes for patients suffering from ulcerative colitis and Crohn’s disease.” About Progenity For more information about Progenity’s products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter. Forward Looking Statements Investor Contact: Media Contact: |
||
|
||
Copyright 2021 GlobeNewswire | Back to overview list |